Cullen Investment Group LTD. Boosts Stock Position in Medtronic PLC $MDT

Cullen Investment Group LTD. increased its position in shares of Medtronic PLC (NYSE:MDT) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,479 shares of the medical technology company’s stock after acquiring an additional 11,375 shares during the period. Medtronic comprises 1.3% of Cullen Investment Group LTD.’s investment portfolio, making the stock its 18th biggest position. Cullen Investment Group LTD.’s holdings in Medtronic were worth $10,191,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Corundum Trust Company INC purchased a new stake in Medtronic during the third quarter worth about $27,000. Board of the Pension Protection Fund purchased a new position in shares of Medtronic in the fourth quarter valued at approximately $29,000. GoalVest Advisory LLC acquired a new position in shares of Medtronic in the fourth quarter valued at approximately $29,000. Valley Wealth Managers Inc. purchased a new stake in Medtronic during the 3rd quarter worth approximately $29,000. Finally, Delos Wealth Advisors LLC purchased a new stake in Medtronic during the 2nd quarter worth approximately $27,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Up 1.5%

Shares of NYSE:MDT opened at $87.84 on Thursday. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company’s 50 day moving average is $96.22 and its two-hundred day moving average is $96.58. The company has a market cap of $112.77 billion, a PE ratio of 24.47, a P/E/G ratio of 2.22 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is presently 79.11%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Distribution deal expands Medtronic’s chronic‑pain portfolio — Medtronic agreed to distribute Merit Medical’s FDA‑cleared ViaVerte basivertebral nerve ablation (BVNA) system, adding a minimally invasive, implant‑free option for chronic vertebrogenic low‑back pain and broadening its interventional pain offering. This can support revenue growth in a high‑demand pain segment. Medtronic and Merit Medical Systems enter into agreement
• Positive Sentiment: FDA expands indication for OmniaSecure lead — The FDA cleared an expanded indication that allows placement of Medtronic’s OmniaSecure defibrillation lead in the left bundle branch area for conduction‑system pacing, strengthening its electrophysiology product lineup and supporting growth in cardiac rhythm management. Medtronic Announces FDA Approval for Expanded Indication of OmniaSecure
• Positive Sentiment: Spin‑off of diabetes unit remains a strategic catalyst — Coverage and commentary note Medtronic’s planned diabetes‑unit spin‑off later this year; separating the high‑growth diabetes business may unlock valuation for both the diabetes standalone and the remaining higher‑margin device franchises. This is a medium‑term positive for investor sentiment. Medtronic to Spin-Off High-Growth Diabetes Unit
• Neutral Sentiment: Analyst sentiment and “undervalued” mentions — Recent writeups and analyst coverage label MDT a moderate buy/undervalued blue‑chip, which can support steadier investor interest but is unlikely to trigger large moves absent fundamentals. Medtronic Given Consensus Rating of “Moderate Buy”
• Negative Sentiment: Guidance cut and charge tied to MiniMed approvals — Medtronic lowered its 2026 earnings outlook, citing a private‑equity related charge connected to MiniMed approval updates. That revision is a direct near‑term earnings headwind and a clear negative on short‑term sentiment. Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval

Analysts Set New Price Targets

Several equities analysts have commented on MDT shares. Robert W. Baird decreased their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Finally, Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, March 1st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).